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Abstract
b-Hydroxy-b-methylbutyrate (HMb) supplementation is used to treat cancer, sepsis and exercise-induced muscle
damage. However, its effects on animal and human health and the consequences of this treatment in other tissues
(e.g., fat and liver) have not been examined. The purpose of this study was to evaluate the effects of HMb
supplementation on skeletal muscle hypertrophy and the expression of proteins involved in insulin signalling. Rats were
treated with HMb (320 mg/kg body weight) or saline for one month. The skeletal muscle hypertrophy and insulin
signalling were evaluated by western blotting, and hormonal concentrations were evaluated using ELISAs. HMb
supplementation induced muscle hypertrophy in the extensor digitorum longus (EDL) and soleus muscles and
increased serum insulin levels, the expression of the mammalian target of rapamycin (mTOR) and phosphorylation of
p70S6K in the EDL muscle. Expression of the insulin receptor was increased only in liver. Thus, our results suggest that
HMb supplementation can be used to increase muscle mass without adverse health effects.
Introduction
The amino acid leucine has been shown to stimulate
skeletal muscle protein synthesis and attenuate muscle
proteolysis. Some of these benefits have been attributed
to the conversion of leucine to its metabolite b-hydroxy-
b-methylbutyrate (HMb) [1-4], which has been shown to
be anti-catabolic and effective at attenuating muscle
atrophy during exercise stress [2,5,6] and in models of
cancer [4,7], congestive heart failure, sepsis, and HIV
[8,9]. According to a review published by Nelo et al.
[10], the dose of HMb supplementation used in the
majority of the previous studies to achieve these effects
was 3 g/day of HMb; use of this dose is based on evi-
dence that it produces better results than 1.5 g/day.
HMb is produced by the transamination of
a-ketoisocaproate (KIC), which is metabolised to isova-
leryl-CoA by the enzyme KIC dioxygenase. The cytosolic
dioxygenase enzyme differs from the mitochondrial KIC
dehydrogenase enzyme in several ways. KIC dioxygenase
produces free HMb in the cytosol, whereas the dehydro-
genase enzyme produces the CoA derivative of isovaleric
acid in the mitochondria [11,12]. Quantitatively, it is
estimated that approximately 5% of all L-leucine oxi-
dised in the human body is converted to HMb.T h e r e -
fore, a subject weighing 70 kg produces approximately
0.2 - 0.4 g HMb/day, depending on the content of leu-
cine in the diet. Because leucine, like all essential amino
acids, is not synthesised in the human body, HMb is
produced from dietary protein [13].
The results of trials evaluating the effect of HMb sup-
plementation on reversing cachexia associated with
rheumatoid arthritis [14], HIV [8], and muscle damage
[15,16] are performed merely with biochemical markers.
Additionally, most of the available studies concerning
the effects of HMb are related to effects on skeletal
muscle, with an absence of relevant information con-
cerning consequences in other peripheral tissues (e.g.,
adipose tissue and liver).
Recently, Holecek et al. [17] demonstrated increases in
protein synthesis in the liver upon HMb supplementation.
However, the authors did not describe the mechanisms
involved in this increase. Moreover, descriptions of the
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exercise or excess catabolism) are scarce.
Taking this into consideration, we aimed to examine
the effect of HMb supplementation on skeletal muscle
hypertrophy in healthy and sedentary rats. The expres-
sion of the mammalian target of rapamycin (mTOR)
and other proteins involved in insulin signalling were
investigated to better understand HMb-stimulated skele-
tal muscle hypertrophy.
Methods
Animals
The Experimental Research Committee of the Federal
University of São Paulo approved all procedures for the
care of the animals used in this study. A total of 14
male Wistar rats ranging in age from 8-9 wks and
weighing between 200 and 250 g were used. They were
housed four per cage, with a chow diet (NUVILAB) and
water ad libitum, in an animal room with a 12 h light-
dark cycle at 22 ± 1°C and 60 ± 5% humidity. The
experiments were carried out after an acclimation period
of one week.
HMb supplementation
Supplementation was carried out by intragastric admin-
istration (gavage) of 320 mg/kg body weight of HMb
(Dymatize Enterprises Inc, Dallas, TX, USA) diluted in
1 . 0m lo fw a t e r .H M b was given daily at the same time
(during the light period) for one month (at 3-4 months
of age). This dose of supplementation was previously
described by our group [4]. The control group was not
submitted to the supplementation protocol and was
treated with water by gavage.
Blood glucose and lipidic profile measurements
Approximately 15-18 hours after HMb oral gavage and
after a 12 hour fast, the animals were euthanised by
decapitation, blood was collected, and serum samples
were collected after allowing the blood to clot on ice.
Serum was stored frozen at -80°C for analysis. Labtest
®
kits were used to assess fasting blood glucose, total cho-
lesterol, high-density lipoprotein (HDL-c) and triacylgly-
cerol (TG) levels. The samples were analysed using an
enzymatic method. LDL-c and VLDL-c were calculated
according to the Friedwald equation ((LDL-c = total
cholesterol-(HDL-c)-(TG/5) and (VLDL = TG/5)) [18],
and LDL-c subclass, which is a good predictive factor
for oxidised-LDL-c, was calculated using the equation
LDL-c = TG/HDL-c [19].
Serum hormone levels
Serum fasting insulin, testosterone and corticosterone
levels were quantified using enzyme-linked immunosor-
bent assay (ELISA). The insulin ELISA kit was obtained
from Millipore Corp. (Bedford, MA, USA), and the tes-
tosterone and corticosterone kits were from Assay
Designs, Inc. (Ann Arbor, MI, USA).
Hepatic content of total lipids
The liver lipids were extracted according to the method
of Folch [20].
Protein analysis by western blotting
After euthanasia, the extensor digitorum longus muscle
(EDL), retroperitoneal adipose tissue (RPAT), and liver
tissues were rapidly removed and homogenised in
1.5 ml extraction buffer (100 mM Trizma, 1% SDS,
100 mM sodium pyrophosphate, 100 mM sodium fluor-
ide, 10 mM EDTA and 10 mM sodium vanadate) and
boiled for 10 min. The extracts were then centrifuged at
12,000 rpm at 4°C for 40 min to remove insoluble mate-
rial. Supernatant protein concentration was determined
using the Bradford dye method with a Bio-Rad reagent
(Bio-Rad Laboratories, Hercules, CA, USA). The pro-
teins were added to Laemmli sample buffer containing
dithiothreitol and boiled for 5 min before loading onto
10% SDS-PAGE gels in a Bio-Rad miniature slab gel
apparatus. Electrotransfer of proteins from the gel to
nitrocellulose was performed for ~1 h at 15 V (constant)
in a Bio-Rad semi-dry transfer apparatus. Nonspecific
protein binding to the nitrocellulose was reduced by
preincubation for 2 h at 22°C in blocking buffer (5%
nonfat dry milk, 10 mM Tris, 150 mM NaCl and 0.02%
Tween 20). The nitrocellulose membranes were sepa-
rately incubated overnight at 4°C with antibodies against
phospho-p70S6K, phospho-Akt, mTOR, GLUT-4, and
Akt/PKB (Cell Signaling Technology
® (Danvers, MA,
USA)) or AMPK, p70S6K, IR (insulin receptor) and
alpha-tubulin antibodies, which were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA),
diluted in blocking buffer added with 1% bovine serum
a l b u m( B S A )a n dt h e nw a s h e df o r3 0m i ni nb l o c k i n g
buffer without BSA. The blots were subsequently incu-
bated with peroxidase-conjugated secondary antibody
for 1 h.
For evaluation of protein loading, membranes were
stripped and reblotted with an anti-alpha-tubulin anti-
body. Specific bands were detected by chemilumines-
cence, and visualisation/capture was performed by
exposure of the membranes to RX films. Band intensi-
ties were quantified by optical densitometry of devel-
oped autoradiographs (Scion Image software-Scion
Corporation, Frederick, Md., USA).
Statistical analysis
The statistical analysis was performed using the Graph-
Pad Prism statistics software package version 5.0 for
Windows (GraphPad Software, San Diego, CA, USA).
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Page 2 of 7The data are expressed as the means ± SEM. Implemen-
tation of the Kolmogorov-Smirnov test revealed that the
results of experiments were distributed normally. The
data were analysed using Student’s t-test for comparison
between two groups. A value of P < 0.05 was considered
statistically significant.
Results
Body mass
HMb treatment induced a significant increase in weight
of the EDL and soleus muscles but did not change the
total body weight, food intake, or fat and liver weight
(Table 1).
Glucose levels, lipidic profile, serum hormone levels and
hepatic total lipid content
HMb supplementation induced a significant increase in
fasting insulin (+245%) and decreases in fasting glucose
(-6%) and corticosterone (-48.7%). There were no differ-
ences in testosterone, lipidic profile, or hepatic total
lipid content. Furthermore, an elevated (+65%) testoster-
one/corticosterone ratio was found in the HMb group
(Table 2).
Muscle protein synthesis (EDL)
HMb supplementation induced a significant increase in
mTOR expression (429.2%) (Figure 1A) and in phos-
phorylation of p70S6K (470%) (Figure 1B). However,
p70S6K expression was not altered (Figure 1C).
Protein expression involved in glucose uptake and insulin
signalling
AMPK and GLUT-4 levels were not altered with HMb
supplementation (Figure 2A and 2B, respectively). The fol-
lowing indicators of insulin signalling were evaluated: IR
expression in the EDL muscle, RPAT and liver; as well as
phosphorylation and expression of Akt/PKB in the EDL
muscle. We observed that HMb supplementation induced
an increase in expression of IR only in the liver (272%)
(Figure 3C). The relative expression levels of IR and Akt/
PKB in the EDL muscle and in the RPAT were not altered
(Figure 3A, B and 3E); the phosphorylation of Akt/PKB in
the EDL muscle was also unchanged (Figure 3D).
Discussion
T h ep r e s e n ts t u d ys o u g h tt oe v a l u a t et h ei m p a c to f
HMb supplementation on the expression of proteins
involved in skeletal muscle hypertrophy in healthy and
sedentary rats and proteins involved in insulin signalling.
Our results show that HMb supplementation increased
mTOR expression and phosphorylation of p70S6K in
the EDL muscle while increasing fasting insulin levels
and testosterone/corticosterone ratios and decreasing
fasting glucose and corticosterone levels in the serum.
As previously described, HMb is a widely studied
metabolite of leucine. Several reports have shown that
branched-chain amino acids (BCAA), isolated leucine
and HMb can stimulate skeletal muscle protein synth-
esis and activate the mTOR pathway in skeletal muscle
[9,21] as well as in primary hepatocytes [22].
In the present study, we observed that, relative to the
control group, the supplemented group demonstrated
an increase in mTOR protein levels and activation of
p70S6K, which are linked to increased skeletal muscle
mass in the EDL muscle. Our findings are supported by
a recent study by Lang’s group [23] showing that gastro-
cnemius mass and protein synthesis were robustly
decreased in mTOR heterozygous mice compared to
wild type mice. Based on this information, we conclude
that not only the activity but also the level of mTOR is
an important regulator of skeletal muscle mass.
Contrary to what was observed in the present study,
Ostaszewski et al. [24] and Holecek et al. [17] did not
observe increased protein synthesis in the EDL and
soleus muscles after HMb supplementation but measured
consistently decreased protein degradation, as estimated
by the net release of tyrosine from incubated muscles.
In the present study, we analysed the expression of
AMPK, which is known to be an important regulator of
muscle protein synthesis [25,26], but we found no differ-
ences between the groups.
In the present study, we found no alterations in the
Akt/PKB pathway in the EDL muscle. Thus, we suggest
that increased skeletal muscle protein mass by HMb
supplementation was induced directly via increased
mTOR expression and activation of p70S6K and not via
phosphorylation of Akt/PKB. However, as previously
shown in several studies, constitutive activation of Akt/
PKB is capable of inducing skeletal muscle hypertrophy
[27-29], although we did not observe this effect in our
Table 1 Body mass, food intake, and tissues weight of
studied groups
Variables Control (n = 7)
ME ± SEM
HMb (n = 7)
ME ± SEM
P Value
Weight (g) -
Initial 306.10 ± 6.24 307.40 ± 3.65 -
Final 393.80 ± 11.98 409.60 ± 9.81 -
Variation (g) 87.70 102.20 0.163
Food intake (g) 22.01 ± 2.31 22.89 ± 2.43 0.402
EDL (g) 0.156 ± 0.002 0.162 ± 0.001 0.022*
Soleus (g) 0.177 ± 0.006 0.205 ± 0.011 0.024*
RPAT (g) 5.744 ± 0.870 4.624 ± 0.438 0.136
MEAT (g) 2.474 ± 0.225 2.207 ± 0.104 0.151
Liver (g) 11.56 ± 0.13 12.25 ± 0.41 0.110
EDL: extensor digitorum longus muscle, RPAT: retroperitoneal adipose tissue,
MEAT: mesenteric adipose tissue.
*p < 0.05 vs. Control group.
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formed 15-18 hours after HMb oral gavage, we suggest
that the activation of the mTOR/p70S6K pathway per-
sists for many hours after supplementation. However,
Laymans group has shown that peak mTOR and insulin
signaling responses occur shortly after consumption of a
meal (i.e. 1-3 hrs) [30]; considering that our measures
were taken 15-18 hrs after the HMb gavage, and after
an overnight fast, it is possible that we missed certain
signals. Therefore, the acute (1-3 hrs post gavage) effects
of HMB on translation initiation and elongation factors,
as well as insulin signaling warrant further investigation.
In the current study, we investigated the intracellular
signalling pathways involved in increased protein synth-
esis induced by HMB; however, it is important to
remember that potent hormones are secreted in
response to nutrients and might exert robust increases
in protein synthesis and metabolism in several tissues
[31-33]. In the present study, we observed that increased
insulin levels may have resulted in increased mTOR
levels and phosphorylation of p70S6K; however, we have
no data that directly address this idea, and previous
studies [30,34] do not support the idea that typical fast-
ing insulin concentrations (above basal levels) can sti-
mulate the mTOR/p70S6K pathway.
As discussed above, several studies [16,22,26] have
been performed to determine the main mechanism of
action of HMb. Based on the results of this study, we
have outlined the main mechanisms of HMb action as
being related to increases in mTOR/p70S6K pathway
signalling and most likely leading to improved protein
synthesis and muscle hypertrophy. However, it is impor-
tant to note that protein synthesis pathways are extre-
mely redundant, and other important proteins not
evaluated in our study, such as the eukaryotic transla-
tion initiation factor 4E (eIF4E/2B), might play a role in
the observed final response (i.e., muscle hypertrophy).
In accordance with this idea, hormones control anabolic/
catabolic pathways that can favour (insulin, testosterone)
or antagonise (glucocorticoid hormones) [35,36] anabolism
in skeletal muscle. In fact, we observed low serum corticos-
terone levels and high testosterone/corticosterone ratios
after HMb supplementation, which could contribute to
skeletal muscle hypertrophy. Likewise, Olza et al. [37]
Table 2 Hormones, serum, and hepatic content of total lipids parameters of control and HMb groups
Variables Control (n = 7) ME ± SEM HMb (n = 7) ME ± SEM P Value
Glucose (mg/dL) 148.9 ± 4.15 139.8 ± 2.36 0.047*
Insulin (ng/mL) 1.94 ± 0.85 4.75 ± 0.27 0.004*
Testosterone (ng/mL) 6.81 ± 0.38 7.14 ± 0.99 0.380
Corticosterone (ng/mL) 72.75 ± 5.15 37.32 ± 13.00 0.044*
Testosterone/corticosterone ratio 0.093 ± 0.014 0.154 ± 0.065 0.045*
Cholesterol (mg/dL) 177.3 ± 27.37 142.0 ± 13.69 0.166
Triacylglycerols (mg/dL) 169.0 ± 17.36 158.9 ± 8.24 0.327
HDL-c (mg/dL) 35.15 ± 6.18 45.22 ± 5.53 0.253
LDL-c (mg/dL) 152.00 ± 18.30 136.8 ± 12.48 0.265
VLDL (mg/dL) 33.80 ± 3.47 31.79 ± 1.64 0.327
Liver lipid (mg/dL 100 mg tissue) 72.56 ± 2.58 77.90 ± 3.80 0.578
TG/HDL-c ratio 5.64 ± 1.28 4.43 ± 0.12 0.209
HDL-c: high-density lipoprotein, LDL-c: low-density lipoprotein, VLDL-c: very-low-density lipoprotein, TG/HDL ratio: triacylglycerols/high-density lipoprotein ratio.
*p < 0.05 vs. Control group.
Figure 1 The expression of mTOR (289 kDa) (A), phosphorylation of p70S6K (70 kDa) (B) and p70S6K (70 kDa) (C) proteins in the
extensor digitorum longus (EDL) muscle after HMb supplementation and control group by Western blotting. N = 5 for all groups.
Values are Mean ± SEM. * p < 0.05 vs. control.
Pimentel et al. Nutrition & Metabolism 2011, 8:11
http://www.nutritionandmetabolism.com/content/8/1/11
Page 4 of 7observed that in elderly patients, a protein-enriched diet
was able to increase protein synthesis and reduce protein
degradation. Moreover, the reduction in corticosterone and
increase in insulin levels may have favoured the reduction
in fasting blood glucose after HMb supplementation.
Recently, Guo et al. [38] also found improvements in glu-
cose homeostasis after leucine supplementation.
Hepatic lipid levels were not altered, as shown in
Table 2. These results are consistent with the lack of
change in serum lipid levels. Several studies [3,17] have
shown that HMb is metabolised to HMG-CoA and used
for de novo synthesis of cholesterol in certain tissues,
including the liver. However, this conclusion is debata-
ble; Holecek et al. [17] showed increases in serum
Figure 2 The expression of AMPK (63 kDa) (A) and GLUT-4 (45 kDa) (B) proteins in the extensor digitorum longus (EDL) muscle after
HMb supplementation and control group by Western blotting. N = 5 for all groups. Values are Mean ± SEM.
Figure 3 The expression of IR (95 kDa) protein in the extensor digitorum longus (EDL) muscle (A), retroperitoneal adipose tissue
(RPAT) (B) and liver (C), phosphorylation of Akt (60 kDa) (D) and Akt (E) after HMb supplementation and control group by Western
blotting. N = 6 for all groups. Values are Mean ± SEM. * p < 0.05 vs. control.
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Page 5 of 7cholesterol levels after HMb administration, while Nis-
sen and Abumrad [3] showed decreases in LDL-c.
In the present study, we also demonstrated an increase
in skeletal muscle weight (EDL and soleus) in the
absence of changes in total body mass, fat mass or liver
weight. However, is suggesting that other body measures
of body fat, such as the size of different fat deposits, e.g.,
epididymal fat, may have changed.
As stated previously, the effects of HMb supplementa-
tion in peripheral tissues have not been intensely inves-
tigated. In accordance with this, Pedrosa et al. [39]
showed that leucine supplementation increased liver
protein content. However, in this study, we thoroughly
investigated HMb’s effects on proteins involved in insu-
lin signalling, starting with the insulin receptor (IR), and
showed that HMb supplementation stimulated IR
expression in the liver, likely due to mTOR activation.
However, the effects of long-term HMb supplementa-
tion on this outcome are as yet unknown.
In summary, HMb treatment leads to skeletal muscle
hypertrophy via increases in mTOR expression and
decreases in serum corticosterone concentrations. In
addition, HMb supplementation increases IR expression
in the liver compared to control group. Thus, our
results suggest that HMb supplementation can be used
to increase muscle mass without adverse health effects.
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